Andrew Wilhelm, DO
Pulmonary Disease · Jackson, MSNPI 1437237732
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,060 of the $51,023 with a category attached, or 82.4%. 36 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 53.1% of the total. Among pulmonary disease clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $119.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$27K
- Sanofi$9K
- Regeneron Healthcare Solutions, Inc.$8K
- GSK$2K
- AstraZeneca$721
- Pfizer$719
- plus $4K from 30 others
Across 62 payments — averaging $1826.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$108K
- Vertex$5K
- Sanofi US Services Inc.$300
What the payments were for
- Speaking & faculty fees$42,06082%
- Travel & lodging$8682%
- Food & beverage$8,09616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 34 | $27,107 |
| Sanofi | 11 | $8,662 |
| Regeneron Healthcare Solutions, Inc. | 17 | $8,396 |
| GSK | 95 | $1,626 |
| AstraZeneca | 27 | $721 |
| Pfizer | 45 | $719 |
| Boehringer Ingelheim | 35 | $610 |
| Merck | 22 | $394 |
| Actelion Pharmaceuticals US, Inc. | 16 | $350 |
| AbbVie(2 entities) | 17 | $311 |
| Insmed, Inc. | 17 | $213 |
| Mallinckrodt Hospital Products Inc. | 9 | $204 |
| Intuitive Surgical | 4 | $191 |
| Bayer | 9 | $180 |
| United Therapeutics Corporation | 9 | $167 |
| Mallinckrodt Enterprises LLC | 7 | $164 |
| Grifols USA, LLC | 8 | $148 |
| Astellas Pharma US Inc | 6 | $116 |
| Inari Medical, Inc. | 4 | $93 |
| Genentech USA, Inc. | 6 | $88 |
| Pulmonx Corporation | 4 | $72 |
| Ambu Inc. | 2 | $71 |
| La Jolla Pharmaceutical Company | 3 | $49 |
| Mylan Specialty L.p. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Johnson & Johnson | 2 | $36 |
| Gilead | 2 | $34 |
| Verona Pharma, Inc. | 2 | $33 |
| Philips North America LLC | 1 | $31 |
| Novartis | 2 | $29 |
| Mauna Kea Technologies, Inc. | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Vapotherm Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$26,401
- DUPIXENT$20,802
- NUCALA$125
- FASENRA$115
How this compares
$51,023 in reported general payments places this provider in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $127,968 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 79 | $79,601 |
| Dupixent SyringeDupilumab | 20 | $71,500 |
| Dupixent PenDupilumab | 18 | $69,217 |
| Spiriva HandihalerTiotropium Bromide | 34 | $17,166 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $16,014 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $10,275 |
| EliquisApixaban | 11 | $9,553 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,460 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $7,780 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,461 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,357 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 166 | $6,332 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,474 |
| Roflumilast | 57 | $3,946 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,626 | $154,813225 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $721 | $89,876120 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $610 | $22,70147 claims |
| PfizerEliquis | $719 | $9,55311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Jackson
- Demondes HaynesJackson$809K
- Michal SenitkoJackson$185K
- Raymond PortisJackson$39K
- George AbrahamJackson$23K
- Maria RappaiJackson$20K
- Arash SamarghandiJackson$19K
- Kimberly DobbsJackson$14K
- Rajesh PatelJackson$13K
- Charles EvansJackson$12K
- Meredith SloanJackson$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.